HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

This study is testing a combination of three treatments — HAIC (chemotherapy delivered directly into the liver), cadonilimab (a dual immune checkpoint blocker), and regorafenib (an oral targeted drug) — as a second-line treatment for bile duct cancer inside the liver (intrahepatic cholangiocarcinoma) that has stopped responding to standard first-line therapies. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with unresectable intrahepatic cholangiocarcinoma confirmed by biopsy - Your cancer has progressed on or you could not tolerate standard first-line chemotherapy - You have good functional status (ECOG 0–1) and expected survival of at least 3 months - Your liver function is adequate **You may NOT be eligible if...** - You have not tried any prior treatment for this cancer - You have had more than one prior line of systemic therapy - You have significant other organ disease or poor performance status - You have an active severe infection or autoimmune condition Talk to your doctor to see if this trial is right for you.